{"id":"sitagliptin-combined-with-metformin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Gastrointestinal disturbances (nausea, diarrhea, abdominal pain)"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Lactic acidosis (rare, metformin-related)"}]},"_chembl":{"chemblId":"CHEMBL1703","moleculeType":"Small molecule","molecularWeight":"165.63"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs the action of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), thereby enhancing glucose-dependent insulin secretion and reducing glucagon levels. Metformin is a biguanide that decreases hepatic glucose production and increases peripheral glucose uptake and insulin sensitivity. Together, they provide complementary mechanisms for glycemic control in type 2 diabetes.","oneSentence":"Sitagliptin inhibits DPP-4 to increase incretin levels and insulin secretion, while metformin reduces hepatic glucose production and improves insulin sensitivity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:18.078Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06246799","phase":"PHASE3","title":"Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-11-07","conditions":"Type 2 Diabetes (Adult Onset)","enrollment":256},{"nctId":"NCT06851962","phase":"PHASE4","title":"Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2025-05-26","conditions":"Diabetes Mellitus Type 2","enrollment":504},{"nctId":"NCT07365358","phase":"PHASE4","title":"Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients","status":"NOT_YET_RECRUITING","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2026-03","conditions":"Diabete Type 2","enrollment":200},{"nctId":"NCT06560333","phase":"PHASE3","title":"iSGLT2 Inhibitor and a iDPP -4 Inhibitor in Treatment of Type 2 Diabetes Mellitus in Patients Treated With Metformin (TRIAD)","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT06759922","phase":"PHASE4","title":"Glimepiride, Empagliflozin, and Sitagliptin With Metformin for Type 2 Diabetes","status":"COMPLETED","sponsor":"Bahria University","startDate":"2025-01-01","conditions":"Type 2 Diabetes Mellitus","enrollment":172},{"nctId":"NCT01471808","phase":"PHASE4","title":"Effects of Different Early Intensive Therapies on Long-term β-cell Function","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2011-10","conditions":"Diabetes Mellitus, Type 2","enrollment":264},{"nctId":"NCT07076056","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2","status":"COMPLETED","sponsor":"Daewon Pharmaceutical Co., Ltd.","startDate":"2022-10-27","conditions":"Type 2 Diabetes","enrollment":230},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT06952231","phase":"PHASE3","title":"Effect of Sitagliptin and Empagliflozin in Combination With Metformin on Hs-CRP Levels in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Lahore","startDate":"2024-05-21","conditions":"Diabetes Mellitus","enrollment":50},{"nctId":"NCT06875193","phase":"PHASE4","title":"DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes","status":"RECRUITING","sponsor":"Dong Wha Pharmaceutical Co. Ltd.","startDate":"2024-05-28","conditions":"Type2diabetes","enrollment":196},{"nctId":"NCT06613750","phase":"PHASE4","title":"Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity","status":"COMPLETED","sponsor":"Zhibin Xu","startDate":"2024-06-01","conditions":"Type 2 Diabetes Mellitus, Glucotoxicity","enrollment":129},{"nctId":"NCT04017221","phase":"","title":"Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-10-01","conditions":"Diabetes Mellitus, Type 2, Urosepsis, Diabetic Ketoacidosis","enrollment":1249636},{"nctId":"NCT06570980","phase":"","title":"Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.","status":"RECRUITING","sponsor":"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","startDate":"2023-08-25","conditions":"Type 2 Diabetes Mellitus (T2DM), Cost-effectiveness, Sulfonylureas, DPP4 Inhibitors, Metformin","enrollment":200},{"nctId":"NCT05798715","phase":"PHASE1","title":"Bioequivalence Study of of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and Janumet 50/1000 mg F.C.Tablets (Merck Sharp & Dohme, The Netherlands)","status":"COMPLETED","sponsor":"Genuine Research Center, Egypt","startDate":"2022-11-29","conditions":"Healthy","enrollment":30},{"nctId":"NCT01760447","phase":"PHASE3","title":"A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12-07","conditions":"Type 2 Diabetes Mellitus","enrollment":223},{"nctId":"NCT01131182","phase":"PHASE4","title":"Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-13","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":1147},{"nctId":"NCT05167513","phase":"PHASE4","title":"Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Getz Pharma","startDate":"2021-01-01","conditions":"Quality of Life, Type 2 Diabetes, Metformin+Sitagliptin","enrollment":188},{"nctId":"NCT02623998","phase":"PHASE3","title":"Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2016-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":102},{"nctId":"NCT02338921","phase":"PHASE4","title":"Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2015-01","conditions":"Type 2 Diabetes","enrollment":78},{"nctId":"NCT02250794","phase":"PHASE4","title":"Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2014-10","conditions":"Type 2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT02315287","phase":"PHASE4","title":"Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-09","conditions":"Type 2 Diabetes","enrollment":190},{"nctId":"NCT04268563","phase":"PHASE1, PHASE2","title":"Comparing the Effect of Sitagliptin/Metformin and Metformin in PCOS Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2020-01-10","conditions":"Polycystic Ovary Syndrome, Infertility, ART","enrollment":80},{"nctId":"NCT04192292","phase":"NA","title":"Study of Sulphonylurea Synergy With DPP4 Inhibitors","status":"COMPLETED","sponsor":"University of Dundee","startDate":"2019-10-08","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT01557504","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-18","conditions":"Type 2 Diabetes Mellitus","enrollment":25},{"nctId":"NCT02043054","phase":"PHASE3","title":"Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2013-12-16","conditions":"Type 2 Diabetes Mellitus, Cardiovascular Disease","enrollment":90},{"nctId":"NCT03813316","phase":"PHASE4","title":"Approaches To Therapy Escalation In T2D","status":"WITHDRAWN","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2019-05-01","conditions":"Type2 Diabetes","enrollment":""},{"nctId":"NCT01336322","phase":"PHASE2","title":"Metformin and Sitagliptin in Women With Previous Gestational Diabetes","status":"COMPLETED","sponsor":"University of Pisa","startDate":"2011-05","conditions":"Pre-diabetes","enrollment":40},{"nctId":"NCT02188186","phase":"PHASE4","title":"Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-07","conditions":"Type 2 Diabetes","enrollment":200},{"nctId":"NCT02738879","phase":"PHASE3","title":"Randomized Sitagliptin Withdrawal Study (MK-0431-845)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-09","conditions":"Type 2 Diabetes Mellitus","enrollment":746},{"nctId":"NCT02532855","phase":"PHASE3","title":"A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":614},{"nctId":"NCT02099110","phase":"PHASE3","title":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-04-22","conditions":"Type 2 Diabetes Mellitus","enrollment":1233},{"nctId":"NCT01702298","phase":"PHASE3","title":"A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-07","conditions":"Type 2 Diabetes Mellitus","enrollment":42},{"nctId":"NCT01678820","phase":"PHASE3","title":"A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":299},{"nctId":"NCT00993187","phase":"PHASE4","title":"Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-04","conditions":"Type 2 Diabetes Mellitus","enrollment":292},{"nctId":"NCT01709305","phase":"PHASE4","title":"A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-11-08","conditions":"Type 2 Diabetes Mellitus","enrollment":5570},{"nctId":"NCT01590771","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":498},{"nctId":"NCT01462266","phase":"PHASE3","title":"Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-01-13","conditions":"Type 2 Diabetes Mellitus","enrollment":660},{"nctId":"NCT01590797","phase":"PHASE3","title":"A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Insulin With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-254)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-07-10","conditions":"Type 2 Diabetes Mellitus","enrollment":467},{"nctId":"NCT02284893","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-09-09","conditions":"Type 2 Diabetes","enrollment":461},{"nctId":"NCT02147925","phase":"PHASE4","title":"Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-08","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":75},{"nctId":"NCT02567994","phase":"PHASE3","title":"Tenelia Triple Combination Study","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2015-04","conditions":"Type 2 Diabetes Mellitus","enrollment":201},{"nctId":"NCT01856907","phase":"PHASE4","title":"Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM","status":"COMPLETED","sponsor":"Woman's","startDate":"2013-09-28","conditions":"Disorder of Glucose Regulation","enrollment":36},{"nctId":"NCT00532935","phase":"PHASE3","title":"MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-26","conditions":"Type 2 Diabetes Mellitus","enrollment":517},{"nctId":"NCT00482729","phase":"PHASE3","title":"MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-06-19","conditions":"Type 2 Diabetes Mellitus","enrollment":1246},{"nctId":"NCT01076075","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-06-03","conditions":"Type 2 Diabetes Mellitus","enrollment":427},{"nctId":"NCT01332370","phase":"","title":"Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-12","conditions":"Diabetes Mellitus, Type 2","enrollment":5391},{"nctId":"NCT01845831","phase":"PHASE4","title":"Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-08","conditions":"Type 2 Diabetes","enrollment":292},{"nctId":"NCT00885352","phase":"PHASE3","title":"Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-04-15","conditions":"Type 2 Diabetes Mellitus","enrollment":313},{"nctId":"NCT00722371","phase":"PHASE3","title":"MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-09-05","conditions":"Type 2 Diabetes Mellitus","enrollment":1615},{"nctId":"NCT01028391","phase":"PHASE3","title":"30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09-01","conditions":"Type 2 Diabetes Mellitus","enrollment":317},{"nctId":"NCT00541450","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01-15","conditions":"Type 2 Diabetes Mellitus","enrollment":492},{"nctId":"NCT00395343","phase":"PHASE3","title":"Sitagliptin Added-on to Insulin Study (0431-051)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12-11","conditions":"Type 2 Diabetes Mellitus","enrollment":641},{"nctId":"NCT00350779","phase":"PHASE3","title":"Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-06-12","conditions":"Type 2 Diabetes Mellitus","enrollment":262},{"nctId":"NCT03125694","phase":"PHASE3","title":"Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2015-02-01","conditions":"Uncontrolled Type 2 Diabetes Mellitus","enrollment":250},{"nctId":"NCT00789191","phase":"PHASE3","title":"Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":222},{"nctId":"NCT02008682","phase":"PHASE4","title":"The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-12","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":368},{"nctId":"NCT00700817","phase":"PHASE3","title":"The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":665},{"nctId":"NCT01519674","phase":"PHASE4","title":"Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":582},{"nctId":"NCT00838903","phase":"PHASE3","title":"Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-02","conditions":"Diabetes Mellitus, Type 2","enrollment":1049},{"nctId":"NCT00631488","phase":"PHASE2","title":"A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02","conditions":"Diabetes Mellitus, Type 2","enrollment":146},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT02946632","phase":"PHASE3","title":"Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes","status":"UNKNOWN","sponsor":"Korea University Anam Hospital","startDate":"2016-12","conditions":"Diabetes Mellitus, Type II","enrollment":104},{"nctId":"NCT02941445","phase":"PHASE4","title":"Weight Maintenance With Dipeptidyl Peptidase 4 (DPP4) Inhibitor Sitagliptin in Combination With Metformin After Liragludite Induced Weight Loss","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2015-10","conditions":"Polycystic Ovary Syndrome, Body Weight","enrollment":24},{"nctId":"NCT01549964","phase":"PHASE3","title":"Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2012-04","conditions":"Glycemic Control","enrollment":916},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT00806520","phase":"","title":"Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":16},{"nctId":"NCT01834274","phase":"PHASE3","title":"Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes","status":"TERMINATED","sponsor":"Takeda","startDate":"2013-06","conditions":"Diabetes Mellitus, Type 2","enrollment":96},{"nctId":"NCT01785043","phase":"PHASE4","title":"Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users","status":"COMPLETED","sponsor":"Anna Cruceta","startDate":"2013-03","conditions":"DIABETES Mellitus Type 2 Not Well Controlled","enrollment":13},{"nctId":"NCT00929201","phase":"PHASE1","title":"Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-01","conditions":"Type 2 Diabetes Mellitus","enrollment":61},{"nctId":"NCT01357148","phase":"","title":"A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET®) (MK-0431A-235)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03","conditions":"Diabetes Mellitus, Type 2","enrollment":143},{"nctId":"NCT01093794","phase":"PHASE1","title":"Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-04","conditions":"Type 2 Diabetes","enrollment":28},{"nctId":"NCT00106704","phase":"PHASE3","title":"Sulfonylurea Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-03","conditions":"Diabetes Mellitus, Type 2","enrollment":441},{"nctId":"NCT01890629","phase":"PHASE4","title":"Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2013-05","conditions":"Type 2 Diabetes Mellitus","enrollment":69},{"nctId":"NCT01065766","phase":"","title":"Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03","conditions":"Type 2 Diabetes Mellitus","enrollment":4065},{"nctId":"NCT00686634","phase":"PHASE4","title":"Sitagliptin in Combination With Metformin and Sulfonylurea","status":"COMPLETED","sponsor":"Charles Drew University of Medicine and Science","startDate":"2008-01","conditions":"Type 2 Diabetes Mellitus","enrollment":108},{"nctId":"NCT00881530","phase":"PHASE2","title":"Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-03","conditions":"Diabetes Mellitus, Type 2","enrollment":660},{"nctId":"NCT00820573","phase":"PHASE4","title":"Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-10","conditions":"Diabetes","enrollment":16},{"nctId":"NCT01974544","phase":"NA","title":"Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2013-05","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT00855166","phase":"PHASE3","title":"Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-02","conditions":"Type 2 Diabetes Mellitus","enrollment":182},{"nctId":"NCT00851903","phase":"PHASE3","title":"Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-06","conditions":"Diabetes Mellitus, Type 2","enrollment":112},{"nctId":"NCT01624116","phase":"NA","title":"Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes","status":"COMPLETED","sponsor":"Services Hospital, Lahore","startDate":"2011-08","conditions":"Diabetes, Type 2","enrollment":161},{"nctId":"NCT00684528","phase":"PHASE3","title":"A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2008-06","conditions":"Diabetes Type 2","enrollment":1000},{"nctId":"NCT00969566","phase":"PHASE4","title":"Predictive Parameters for Efficacy of Sitagliptin and Metformin Combination","status":"COMPLETED","sponsor":"Seoul National University Bundang Hospital","startDate":"2009-01","conditions":"Diabetes","enrollment":150},{"nctId":"NCT01089790","phase":"PHASE3","title":"Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2010-03","conditions":"Diabetes Mellitus, Type 2","enrollment":141},{"nctId":"NCT00666458","phase":"PHASE3","title":"18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Type 2 Diabetes","enrollment":822},{"nctId":"NCT00842400","phase":"PHASE1","title":"A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.","status":"COMPLETED","sponsor":"VIVUS LLC","startDate":"2009-02","conditions":"Obesity","enrollment":20},{"nctId":"NCT00790348","phase":"","title":"Effect of Januvia on Ghrelin and Other Gut Hormones in Patients With Diabetes","status":"UNKNOWN","sponsor":"Wayne State University","startDate":"2008-07","conditions":"Type 2 Diabetes","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Januvia®, Merck & Co. Inc."],"phase":"marketed","status":"active","brandName":"Sitagliptin combined with metformin","genericName":"Sitagliptin combined with metformin","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sitagliptin inhibits DPP-4 to increase incretin levels and insulin secretion, while metformin reduces hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}